{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:58:59Z","timestamp":1792681139541,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/nrneurol.2009.219","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T07:14:23Z","timestamp":1265613263000},"page":"108-119","source":"Crossref","is-referenced-by-count":309,"title":["Can Alzheimer disease be prevented by amyloid-\u03b2 immunotherapy?"],"prefix":"10.1038","volume":"6","author":[{"given":"Cynthia A.","family":"Lemere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrneurol2009219_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186\u2013191 (2007).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2009219_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005072-199704000-00001","volume":"56","author":"DW Dickson","year":"1997","unstructured":"Dickson, D. W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56, 321\u2013339 (1997).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2009219_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"BFnrneurol2009219_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/scientificamerican0506-72","volume":"294","author":"MS Wolfe","year":"2006","unstructured":"Wolfe, M. S. Shutting down Alzheimer's. Sci. Am. 294, 72\u201379 (2006).","journal-title":"Sci. Am."},{"key":"BFnrneurol2009219_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741\u2013766 (2001).","journal-title":"Physiol. Rev."},{"key":"BFnrneurol2009219_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0197-0186(02)00050-5","volume":"41","author":"W Klein","year":"2002","unstructured":"Klein, W. A\u03b2 toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345\u2013352 (2002).","journal-title":"Neurochem. Int."},{"key":"BFnrneurol2009219_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","volume":"44","author":"DM Walsh","year":"2004","unstructured":"Walsh, D. M. & Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181\u2013193 (2004).","journal-title":"Neuron"},{"key":"BFnrneurol2009219_CR8","unstructured":"ClinicalTrials.gov [online], (2009)."},{"key":"BFnrneurol2009219_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"B Solomon","year":"1996","unstructured":"Solomon, B., Koppel, R., Hanan, E. & Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer \u03b2-amyloid peptide. Proc. Natl Acad. Sci. USA 93, 452\u2013455 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR10","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","volume":"94","author":"B Solomon","year":"1997","unstructured":"Solomon, B., Koppel, R., Frenkel, D. & Hanan-Aharon, E. Disaggregation of Alzheimer \u03b2-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94, 4109\u20134112 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D.  et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999).","journal-title":"Nature"},{"key":"BFnrneurol2009219_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1749-6632.2000.tb06943.x","volume":"920","author":"CA Lemere","year":"2000","unstructured":"Lemere, C. A.  et al. Nasal A\u03b2 treatment induces anti-A\u03b2 antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920, 328\u2013331 (2000).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol2009219_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","volume":"48","author":"HL Weiner","year":"2000","unstructured":"Weiner, H. L.  et al. Nasal administration of amyloid-\u03b2 peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567\u2013579 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","volume":"22","author":"P Das","year":"2001","unstructured":"Das, P., Murphy, M., Younkin, L., Younkin, S. & Golde, T. Reduced effectiveness of A\u03b21\u201342 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22, 721\u2013727 (2001).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9440(10)61715-4","volume":"159","author":"EM Sigurdsson","year":"2001","unstructured":"Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B. & Wisniewski, T. Immunization with a nontoxic\/nonfibrillar amyloid-\u03b2 homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439\u2013447 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2009219_CR16","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1523\/JNEUROSCI.0381-06.2006","volume":"26","author":"M Maier","year":"2006","unstructured":"Maier, M.  et al. Short amyloid-\u03b2 (A\u03b2) immunogens reduce cerebral A\u03b2 load and learning deficits in an Alzheimer's disease mouse model in the absence of an A\u03b2-specific cellular immune response. J. Neurosci. 26, 4717\u20134728 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus, C.  et al. A\u03b2 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979\u2013982 (2000).","journal-title":"Nature"},{"key":"BFnrneurol2009219_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan, D.  et al. A\u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982\u2013985 (2000).","journal-title":"Nature"},{"key":"BFnrneurol2009219_CR19","doi-asserted-by":"publisher","first-page":"39413","DOI":"10.1074\/jbc.M608485200","volume":"281","author":"S Oddo","year":"2006","unstructured":"Oddo, S.  et al. Reduction of soluble A\u03b2 and tau, but not soluble A\u03b2 alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413\u201339423 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2009219_CR20","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1523\/JNEUROSCI.0208-08.2008","volume":"28","author":"E Head","year":"2008","unstructured":"Head, E.  et al. A two-year study with fibrillar \u03b2-amyloid (A\u03b2) immunization in aged canines: effects on cognitive function and brain A\u03b2. J. Neurosci. 28, 3555\u20133566 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/10445490152717569","volume":"20","author":"CA Lemere","year":"2001","unstructured":"Lemere, C. A., Maron, R., Selkoe, D. J. & Weiner, H. L. Nasal vaccination with \u03b2-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 20, 705\u2013711 (2001).","journal-title":"DNA Cell Biol."},{"key":"BFnrneurol2009219_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0304-3940(01)01951-6","volume":"307","author":"T Town","year":"2001","unstructured":"Town, T.  et al. Characterization of murine immunoglobulin G antibodies against human amyloid-\u03b21\u201342 . Neurosci. Lett. 307, 101\u2013104 (2001).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol2009219_CR23","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin, J.  et al. Therapeutically effective antibodies against amyloid-\u03b2 peptide target amyloid-\u03b2 residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263\u20131269 (2002).","journal-title":"Nat. Med."},{"key":"BFnrneurol2009219_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intimm\/dxg049","volume":"15","author":"DH Cribbs","year":"2003","unstructured":"Cribbs, D. H.  et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with \u03b2-amyloid. Int. Immunol. 15, 505\u2013514 (2003).","journal-title":"Int. Immunol."},{"key":"BFnrneurol2009219_CR25","doi-asserted-by":"publisher","first-page":"15659","DOI":"10.1073\/pnas.0705888104","volume":"104","author":"AS Gardberg","year":"2007","unstructured":"Gardberg, A. S.  et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl Acad. Sci. USA 104, 15659\u201315664 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR26","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.1073\/pnas.191118298","volume":"98","author":"A Monsonego","year":"2001","unstructured":"Monsonego, A., Maron, R., Zota, V., Selkoe, D. & Weiner, H. Immune hyporesponsiveness to amyloid-\u03b2 peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 10273\u201310278 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0197-4580(03)00036-8","volume":"24","author":"P Das","year":"2003","unstructured":"Das, P., Chapoval, S., Howard, V., David, C. S. & Golde, T. E. Immune responses against A\u03b21\u201342 in HLA class II transgenic mice: implications for A\u03b21\u201342 immune-mediated therapies. Neurobiol. Aging 24, 969\u2013976 (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR28","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"R DeMattos","year":"2001","unstructured":"DeMattos, R.  et al. Peripheral anti-A\u03b2 antibody alters CNS and plasma clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850\u20138855 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR29","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard, F.  et al. Epitope and isotype specificities of antibodies to \u03b2-amyloid for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA 100, 2023\u20132028 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F.  et al. Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916\u2013919 (2000).","journal-title":"Nat. Med."},{"key":"BFnrneurol2009219_CR31","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","volume":"22","author":"LA Kotilinek","year":"2002","unstructured":"Kotilinek, L. A.  et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331\u20136335 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart, J. C.  et al. Immunization reverses memory deficits without reducing brain A\u03b2 burden in Alzheimer's disease model. Nat. Neurosci. 5, 452\u2013457 (2002).","journal-title":"Nat. Neurosci."},{"key":"BFnrneurol2009219_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer, M.  et al. Cerebral hemorrhage after passive anti-A\u03b2 immunotherapy. Science 298, 1379 (2002).","journal-title":"Science"},{"key":"BFnrneurol2009219_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke, M. M.  et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid \u03b2. J. Neurosci. 25, 629\u2013636 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock, D. M.  et al. Passive immunotherapy against A\u03b2 in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1, 24 (2004).","journal-title":"J. Neuroinflammation"},{"key":"BFnrneurol2009219_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. A\u03b2 immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321\u2013332 (2004).","journal-title":"Neuron"},{"key":"BFnrneurol2009219_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jnr.10286","volume":"69","author":"NB Chauhan","year":"2002","unstructured":"Chauhan, N. B. & Siegel, G. J. Reversal of amyloid \u03b2 toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid \u03b2 antibody. J. Neurosci. Res. 69, 10\u201323 (2002).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol2009219_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jnr.10721","volume":"74","author":"NB Chauhan","year":"2003","unstructured":"Chauhan, N. B. & Siegel, G. J. Intracerebroventricular passive immunization with anti-A\u03b2 antibody in Tg2576. J. Neurosci. Res. 74, 142\u2013147 (2003).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol2009219_CR39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nm1234","volume":"11","author":"I Klyubin","year":"2005","unstructured":"Klyubin, I.  et al. Amyloid \u03b2 protein immunotherapy neutralizes A\u03b2 oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556\u2013561 (2005).","journal-title":"Nat. Med."},{"key":"BFnrneurol2009219_CR40","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1523\/JNEUROSCI.5161-07.2008","volume":"28","author":"I Klyubin","year":"2008","unstructured":"Klyubin, I.  et al. Amyloid \u03b2 protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28, 4231\u20134237 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.nbd.2008.10.011","volume":"33","author":"TL Spires-Jones","year":"2009","unstructured":"Spires-Jones, T. L.  et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol. Dis. 33, 213\u2013220 (2009).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol2009219_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer, A. J.  et al. Evaluation of the safety and immunogenicity of synthetic A\u03b242 (AN1792) in patients with AD. Neurology 64, 94\u2013101 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo, J. M.  et al. Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization. Neurology 61, 46\u201354 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman, S.  et al. Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1750-3639.2005.tb00102.x","volume":"15","author":"T Wisniewski","year":"2005","unstructured":"Wisniewski, T. & Frangione, B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 15, 72\u201377 (2005).","journal-title":"Brain Pathol."},{"key":"BFnrneurol2009219_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000113700","volume":"5","author":"M Pride","year":"2008","unstructured":"Pride, M.  et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 5, 194\u2013196 (2008).","journal-title":"Neurodegener. Dis."},{"key":"BFnrneurol2009219_CR47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.20592","volume":"58","author":"M Lee","year":"2005","unstructured":"Lee, M.  et al. A\u03b242 immunization in Alzheimer's disease generates A\u03b2 N-terminal antibodies. Ann. Neurol. 58, 430\u2013435 (2005).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI200318104","volume":"112","author":"A Monsonego","year":"2003","unstructured":"Monsonego, A.  et al. Increased T cell reactivity to amyloid \u03b2 protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112, 415\u2013422 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2009219_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock, C.  et al. Antibodies against \u03b2-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547\u2013554 (2003).","journal-title":"Neuron"},{"key":"BFnrneurol2009219_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"B Vellas","year":"2009","unstructured":"Vellas, B. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144\u2013151 (2009).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrneurol2009219_CR51","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","volume":"64","author":"NC Fox","year":"2005","unstructured":"Fox, N. C.  et al. Effects of A\u03b2 immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563\u20131572 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00005072-199311000-00009","volume":"52","author":"E Masliah","year":"1993","unstructured":"Masliah, E.  et al. Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 52, 619\u2013632 (1993).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2009219_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/BF00293315","volume":"87","author":"E Braak","year":"1994","unstructured":"Braak, E., Braak, H. & Mandelkow, E. M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554\u2013567 (1994).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2009219_CR54","first-page":"197","volume-title":"Alzheimer Disease","author":"P Hof","year":"1994","unstructured":"Hof, P. & Morrison, J. in Alzheimer Disease (eds Terry, R., Katzman, R. & Bick, K.) 197\u2013230 (Raven Press, New York, 1994)."},{"key":"BFnrneurol2009219_CR55","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","volume":"2","author":"EK Perry","year":"1978","unstructured":"Perry, E. K.  et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2, 1457\u20131459 (1978).","journal-title":"Br. Med. J."},{"issue":"Suppl. 2","key":"BFnrneurol2009219_CR56","first-page":"1","volume":"9","author":"E Perry","year":"1995","unstructured":"Perry, E. Cholinergic signaling in Alzheimer disease: therapeutic strategies. Alzheimer Dis. Assoc. Disord. 9 (Suppl. 2), 1\u20132 (1995).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrneurol2009219_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1750-3639.1993.tb00725.x","volume":"3","author":"JQ Trojanowski","year":"1993","unstructured":"Trojanowski, J. Q.  et al. Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol. 3, 45\u201354 (1993).","journal-title":"Brain Pathol."},{"key":"BFnrneurol2009219_CR58","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry, R. D.  et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572\u2013580 (1991).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-3940(94)90121-X","volume":"74","author":"E Masliah","year":"1994","unstructured":"Masliah, E.  et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 74, 67\u201372 (1994).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol2009219_CR60","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1126\/science.1105681","volume":"307","author":"GB Stokin","year":"2005","unstructured":"Stokin, G. B.  et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282\u20131288 (2005).","journal-title":"Science"},{"key":"BFnrneurol2009219_CR61","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","volume":"25","author":"TL Spires","year":"2005","unstructured":"Spires, T. L.  et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278\u20137287 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR62","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1023\/B:NEUR.0000044197.83514.64","volume":"33","author":"DL Moolman","year":"2004","unstructured":"Moolman, D. L., Vitolo, O. V., Vonsattel, J. P. & Shelanski, M. L. Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 33, 377\u2013387 (2004).","journal-title":"J. Neurocytol."},{"key":"BFnrneurol2009219_CR63","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes, C.  et al. Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216\u2013223 (2008).","journal-title":"Lancet"},{"key":"BFnrneurol2009219_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer, I., Boada Rovira, M., S\u00e1nchez Guerra, M. L., Rey, M. J. & Costa-Juss\u00e1, F. Neuropathology and pathogenesis of encephalitis following amyloid-\u03b2 immunization in Alzheimer's disease. Brain Pathol. 14, 11\u201320 (2004).","journal-title":"Brain Pathol."},{"key":"BFnrneurol2009219_CR65","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JA Nicoll","year":"2006","unstructured":"Nicoll, J. A.  et al. A\u03b2 species removal after A\u03b242 immunization. J. Neuropathol. Exp. Neurol. 65, 1040\u20131048 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2009219_CR66","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/archneur.64.4.583","volume":"64","author":"S Bombois","year":"2007","unstructured":"Bombois, S.  et al. Absence of \u03b2-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol. 64, 583\u2013587 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009219_CR67","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","volume":"64","author":"E Masliah","year":"2005","unstructured":"Masliah, E.  et al. A\u03b2 vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129\u2013131 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR68","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","volume":"169","author":"RL Patton","year":"2006","unstructured":"Patton, R. L.  et al. Amyloid-\u03b2 peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169, 1048\u20131063 (2006).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2009219_CR69","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche, D.  et al. Consequence of A\u03b2 immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299\u20133310 (2008).","journal-title":"Brain"},{"key":"BFnrneurol2009219_CR70","first-page":"T166","volume":"4","author":"M Grundman","year":"2008","unstructured":"Grundman M. & Black, R. Clinical trials of bapineuzumab, a \u03b2-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease [abstract O3-04-05]. Alzheimers Dementia 4, T166 (2008).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR71","unstructured":"Elan and Wyeth plan to amend bapineuzumab phase 3 protocols. Press release [online], (2009)."},{"key":"BFnrneurol2009219_CR72","first-page":"T774","volume":"4","author":"ER Siemers","year":"2008","unstructured":"Siemers, E. R.  et al. Safety, tolerability and biomarker effects of an A\u03b2 monoclonal antibody administered to patients with Alzheimer's disease [abstract P4\u2013346]. Alzheimers Dementia 4, T774 (2008).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR73","first-page":"P258","volume":"5","author":"ER Siemers","year":"2009","unstructured":"Siemers, E. R.  et al. Measurement of cerebrospinal fluid total tau and phospho-tau in phase 2 trials of therapies targeting A\u03b2 [abstract]. Alzheimers Dementia 5, P258 (2009).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR74","first-page":"P156","volume":"5","author":"RB De Mattos","year":"2009","unstructured":"De Mattos, R. B.  et al. Identification, characterization, and comparison of amino-terminally truncated A\u03b242 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment [abstract]. Alzheimers Dementia 5, P156\u2013P157 (2009).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR75","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1016\/j.jalz.2008.05.191","volume":"4","author":"NR Relkin","year":"2008","unstructured":"Relkin, N. R. Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin [abstract S1-02-02]. Alzheimers Dementia 4, T101 (2008).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR76","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/brain\/awg191","volume":"126","author":"Y Du","year":"2003","unstructured":"Du, Y.  et al. Human anti-\u03b2-amyloid antibodies block \u03b2-amyloid fibril formation and prevent \u03b2-amyloid-induced neurotoxicity. Brain 126, 1935\u20131939 (2003).","journal-title":"Brain"},{"key":"BFnrneurol2009219_CR77","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/jnr.20734","volume":"83","author":"QL Ma","year":"2006","unstructured":"Ma, Q. L.  et al. Antibodies against \u03b2-amyloid reduce A\u03b2 oligomers, glycogen synthase kinase-3\u03b2 activation and \u03c4 phosphorylation in vivo and in vitro. J. Neurosci. Res. 83, 374\u2013384 (2006).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol2009219_CR78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jnr.20886","volume":"84","author":"G Istrin","year":"2006","unstructured":"Istrin, G., Bosis, E. & Solomon, B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-\u03b2 peptide. J. Neurosci. Res. 84, 434\u2013443 (2006).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol2009219_CR79","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"RC Dodel","year":"2004","unstructured":"Dodel, R. C.  et al. Intravenous immunoglobulins containing antibodies against \u03b2-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472\u20131474 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009219_CR80","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","volume":"30","author":"NR Relkin","year":"2008","unstructured":"Relkin, N. R.  et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728\u20131736 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR81","volume-title":"Alzheimer Research Forum","author":"G Strobel","year":"2009","unstructured":"Strobel, G. An eFAD prevention trial\u2014one man's view. Alzheimer Research Forum [online], (2009)."},{"key":"BFnrneurol2009219_CR82","first-page":"P113","volume":"5","author":"G Bengt","year":"2009","unstructured":"Bengt, G. Results of the first-in-man study with the active A\u03b2 immunotherapy CAD106 in Alzheimer patients [abstract]. Alzheimers Dementia 5, P113\u2013P114 (2009).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR83","doi-asserted-by":"publisher","first-page":"P257","DOI":"10.1016\/j.jalz.2009.04.281","volume":"5","author":"A Schneeberger","year":"2009","unstructured":"Schneeberger, A., Mandler, M., Zauner, W., Mattner, F. & Schmidt, W. Development of Alzheimer AFFITOPE vaccines\u2014from concept to clinical testing [abstract]. Alzheimers Dementia 5, P257 (2009).","journal-title":"Alzheimers Dementia"},{"key":"BFnrneurol2009219_CR84","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan, A. M.  et al. Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343\u2013349 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009219_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N.  et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393 (2009).","journal-title":"JAMA"},{"key":"BFnrneurol2009219_CR86","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.21559","volume":"65","author":"AM Fagan","year":"2009","unstructured":"Fagan, A. M.  et al. Decreased cerebrospinal fluid A\u03b242 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176\u2013183 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR87","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","volume":"30","author":"JL Price","year":"2009","unstructured":"Price, J. L.  et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30, 1026\u20131036 (2009).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR88","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.nbd.2008.10.003","volume":"35","author":"R Craig-Schapiro","year":"2009","unstructured":"Craig-Schapiro, R., Fagan, A. M. & Holtzman, D. M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 35, 128\u2013140 (2009).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol2009219_CR89","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1212\/01.wnl.0000280577.43413.d9","volume":"70","author":"NE Carlson","year":"2008","unstructured":"Carlson, N. E.  et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 70, 828\u2013833 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR90","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis, C. A.  et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46, 2740\u20132754 (2003).","journal-title":"J. Med. Chem."},{"key":"BFnrneurol2009219_CR91","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.20889","volume":"60","author":"HA Archer","year":"2006","unstructured":"Archer, H. A.  et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 60, 145\u2013147 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR92","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"W Klunk","year":"2004","unstructured":"Klunk, W.  et al. Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR93","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"A Fagan","year":"2006","unstructured":"Fagan, A.  et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann. Neurol. 59, 512\u2013519 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009219_CR94","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike, K. E.  et al. \u03b2-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837\u20132844 (2007).","journal-title":"Brain"},{"key":"BFnrneurol2009219_CR95","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe, C. C.  et al. Imaging \u03b2-amyloid burden in aging and dementia. Neurology 68, 1718\u20131725 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2009219_CR96","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awn320","volume":"132","author":"EC Mormino","year":"2008","unstructured":"Mormino, E. C.  et al. Episodic memory loss is related to hippocampal-mediated \u03b2-amyloid deposition in elderly subjects. Brain 132, 1310\u20131323 (2008).","journal-title":"Brain"},{"key":"BFnrneurol2009219_CR97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)64700-1","volume":"156","author":"GK Gouras","year":"2000","unstructured":"Gouras, G. K.  et al. Intraneuronal A\u03b242 accumulation in human brain. Am. J. Pathol. 156, 15\u201320 (2000).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2009219_CR98","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1074\/jbc.M700373200","volume":"282","author":"D Tampellini","year":"2007","unstructured":"Tampellini, D.  et al. Internalized antibodies to the A\u03b2 domain of APP reduce neuronal A\u03b2 and protect against synaptic alterations. J. Biol. Chem. 282, 18895\u201318906 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2009219_CR99","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2174\/156720507781788792","volume":"4","author":"M Arbel","year":"2007","unstructured":"Arbel, M. & Solomon, B. A novel immunotherapy for Alzheimer's disease: antibodies against the \u03b2-secretase cleavage site of APP. Curr. Alzheimer Res. 4, 437\u2013445 (2007).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrneurol2009219_CR100","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1086\/590150","volume":"47","author":"RB Effros","year":"2008","unstructured":"Effros, R. B.  et al. Workshop on HIV infection and aging: what is known and future research directions. Clin. Infect. Dis. 47, 542\u2013553 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneurol2009219_CR101","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/187152709787847298","volume":"8","author":"A Ghochikyan","year":"2009","unstructured":"Ghochikyan, A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol. Disord. Drug Targets 8, 128\u2013143 (2009).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"BFnrneurol2009219_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe, D. J. The molecular pathology of Alzheimer's disease. Neuron 6, 487\u2013498 (1991).","journal-title":"Neuron"},{"key":"BFnrneurol2009219_CR103","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"J Hardy","year":"1992","unstructured":"Hardy, J. & Higgins, G. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"key":"BFnrneurol2009219_CR104","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.emboj.7601930","volume":"27","author":"KF Winklhofer","year":"2008","unstructured":"Winklhofer, K. F., Tatzelt, J. & Haass, C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336\u2013349 (2008).","journal-title":"EMBO J."},{"key":"BFnrneurol2009219_CR105","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1523\/JNEUROSCI.0395-07.2007","volume":"27","author":"M Knobloch","year":"2007","unstructured":"Knobloch, M., Farinelli, M., Konietzko, U., Nitsch, R. M. & Mansuy, I. M. A\u03b2 oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J. Neurosci. 27, 7648\u20137653 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR106","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar, G. M.  et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837\u2013842 (2008).","journal-title":"Nat. Med."},{"key":"BFnrneurol2009219_CR107","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/nature07767","volume":"457","author":"A Nikolaev","year":"2009","unstructured":"Nikolaev, A., McLaughlin, T., O'Leary, D. D. & Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981\u2013989 (2009).","journal-title":"Nature"},{"key":"BFnrneurol2009219_CR108","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mp.2008.105","volume":"14","author":"T Chiba","year":"2009","unstructured":"Chiba, T.  et al. Amyloid-\u03b2 causes memory impairment by disturbing the JAK2\/STAT3 axis in hippocampal neurons. Mol. Psychiatry 14, 206\u2013222 (2009).","journal-title":"Mol. Psychiatry"},{"key":"BFnrneurol2009219_CR109","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2000.tb05554.x","volume":"924","author":"DJ Selkoe","year":"2000","unstructured":"Selkoe, D. J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924, 17\u201325 (2000).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol2009219_CR110","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S0264-410X(02)00609-6","volume":"21","author":"D Frenkel","year":"2003","unstructured":"Frenkel, D., Dewachter, I., Van Leuven, F. & Solomon, B. Reduction of \u03b2-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21, 1060\u20131065 (2003).","journal-title":"Vaccine"},{"key":"BFnrneurol2009219_CR111","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","volume":"174","author":"MG Agadjanyan","year":"2005","unstructured":"Agadjanyan, M. G.  et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from \u03b2-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 1580\u20131586 (2005).","journal-title":"J. Immunol."},{"key":"BFnrneurol2009219_CR112","doi-asserted-by":"publisher","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","volume":"27","author":"I Petrushina","year":"2007","unstructured":"Petrushina, I.  et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric A\u03b2 species in amyloid precursor protein transgenic mice. J. Neurosci. 27, 12721\u201312731 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR113","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neurobiolaging.2006.04.007","volume":"28","author":"TJ Seabrook","year":"2006","unstructured":"Seabrook, T. J.  et al. Dendrimeric A\u03b21\u201315 is an effective immunogen in wildtype and APP tg mice. Neurobiol. Aging 28, 813\u2013823 (2006).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.neurobiolaging.2004.04.006","volume":"26","author":"WJ Bowers","year":"2005","unstructured":"Bowers, W. J.  et al. HSV amplicon-mediated A\u03b2 vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging 26, 393\u2013407 (2005).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR115","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","volume":"25","author":"CY Wang","year":"2007","unstructured":"Wang, C. Y.  et al. Site-specific UBITh amyloid-\u03b2 vaccine for immunotherapy of Alzheimer's disease. Vaccine 25, 3041\u20133052 (2007).","journal-title":"Vaccine"},{"key":"BFnrneurol2009219_CR116","doi-asserted-by":"publisher","first-page":"9619","DOI":"10.1073\/pnas.0600966103","volume":"103","author":"Y Okura","year":"2006","unstructured":"Okura, Y.  et al. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc. Natl Acad. Sci. USA 103, 9619\u20139624 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR117","doi-asserted-by":"publisher","first-page":"e2124","DOI":"10.1371\/journal.pone.0002124","volume":"3","author":"N Movsesyan","year":"2008","unstructured":"Movsesyan, N.  et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine\u2014a novel immunotherapeutic strategy. PLoS ONE 3, e2124 (2008).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2009219_CR118","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jneuroim.2008.08.016","volume":"205","author":"N Movsesyan","year":"2008","unstructured":"Movsesyan, N.  et al. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-\u03b2 antibody production and polarizes the immune response towards a Th2 phenotype. J. Neuroimmunol. 205, 57\u201363 (2008).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2009219_CR119","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.4049\/jimmunol.0803366","volume":"182","author":"P Bach","year":"2009","unstructured":"Bach, P.  et al. Vaccination with A\u03b2-displaying virus-like particles reduces soluble and insoluble cerebral A\u03b2 and lowers plaque burden in APP transgenic mice. J. Immunol. 182, 7613\u20137624 (2009).","journal-title":"J. Immunol."},{"key":"BFnrneurol2009219_CR120","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1074\/jbc.M511018200","volume":"281","author":"EB Lee","year":"2006","unstructured":"Lee, E. B.  et al. Targeting amyloid-\u03b2 peptide (A\u03b2) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A\u03b2 precursor protein (APP) transgenic mice. J. Biol. Chem. 281, 4292\u20134299 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2009219_CR121","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1471-4159.2006.04157.x","volume":"100","author":"MP Lambert","year":"2007","unstructured":"Lambert, M. P.  et al. Monoclonal antibodies that target pathological assemblies of A\u03b2. J. Neurochem. 100, 23\u201335 (2007).","journal-title":"J. Neurochem."},{"key":"BFnrneurol2009219_CR122","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","volume":"26","author":"Y Levites","year":"2006","unstructured":"Levites, Y.  et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid \u03b240, and amyloid \u03b242 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 26, 11923\u201311928 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR123","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neurobiolaging.2007.06.013","volume":"30","author":"YJ Wang","year":"2009","unstructured":"Wang, Y. J.  et al. Intramuscular delivery of a single chain antibody gene reduces brain A\u03b2 burden in a mouse model of Alzheimer's disease. Neurobiol. Aging 30, 364\u2013376 (2009).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009219_CR124","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jmb.2009.01.061","volume":"387","author":"G Meli","year":"2009","unstructured":"Meli, G., Visintin, M., Cannistraci, I. & Cattaneo, A. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-\u03b2 oligomers. J. Mol. Biol. 387, 584\u2013606 (2009).","journal-title":"J. Mol. Biol."},{"key":"BFnrneurol2009219_CR125","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/mt.2009.174","volume":"17","author":"K Sudol","year":"2009","unstructured":"Sudol, K.  et al. Generating differentially targeted amyloid-\u03b2 specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol. Ther. 17, 2031\u20132040 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2009219_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jneuroim.2009.06.003","volume":"213","author":"G Acero","year":"2009","unstructured":"Acero, G.  et al. Immunodominant epitope and properties of pyroglutamate-modified A\u03b2-specific antibodies produced in rabbits. J. Neuroimmunol. 213, 39\u201346 (2009).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2009219_CR127","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1523\/JNEUROSCI.23-24-08532.2003","volume":"23","author":"P Das","year":"2003","unstructured":"Das, P.  et al. Amyloid-\u03b2 immunization effectively reduces amyloid deposition in FcR\u03b3\u2212\/\u2212 knock-out mice. J. Neurosci. 23, 8532\u20138538 (2003).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR128","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai, B. J.  et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-\u03b2 in vivo by immunotherapy. J. Neurosci. 22, 7873\u20137878 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR129","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0969-9961(03)00044-5","volume":"14","author":"CA Lemere","year":"2003","unstructured":"Lemere, C. A.  et al. Evidence for peripheral clearance of cerebral A\u03b2 protein following chronic, active A\u03b2 immunization in PSAPP mice. Neurobiol. Dis. 14, 10\u201318 (2003).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol2009219_CR130","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","volume":"29","author":"K Yamada","year":"2009","unstructured":"Yamada, K.  et al. A\u03b2 immunotherapy: intracerebral sequestration of A\u03b2 by an anti-A\u03b2 monoclonal antibody 266 with high affinity to soluble A\u03b2. J. Neurosci. 29, 11393\u201311398 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009219_CR131","doi-asserted-by":"publisher","first-page":"12145","DOI":"10.1073\/pnas.0904866106","volume":"106","author":"M Britschgi","year":"2009","unstructured":"Britschgi, M.  et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 12145\u201312150 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009219_CR132","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","volume":"37","author":"ME Weksler","year":"2002","unstructured":"Weksler, M. E.  et al. Patients with Alzheimer's disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37, 943\u2013948 (2002).","journal-title":"Exp. Gerontol."}],"updated-by":[{"DOI":"10.1038\/nrneurol.2010.47","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000}},{"DOI":"10.1038\/nrneurol.2010.68","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000}}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:05:44Z","timestamp":1649919944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["BFnrneurol2009219"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2009.219","relation":{"correction":[{"id-type":"doi","id":"10.1038\/nrneurol.2010.68","asserted-by":"object"},{"id-type":"doi","id":"10.1038\/nrneurol.2010.47","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}